ReviewFrontiers in medicine2026
Evolution and economic evaluation of fecal incontinence management in United States intensive care units: from historical containment to automated diversion.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fecal incontinence (FI) poses a significant clinical and economic challenge in the U.S. intensive care units (ICUs), affecting 9-40% of patients and contributing to billions of dollars in healthcare costs mainly towards complications such as incontinence-associated dermatitis (IAD), hospital-acquired pressure injuries (HAPI), and Clostridioides difficile infection (CDI). This review traces the evolution of FI management from rudimentary containment methods to the newest innovative Qoramatic Automated Stool Management (ASM) system with no balloon and zero radial pressure. We compared Qoramatic ASM to traditional absorbent pads and indwelling balloon catheters (IBCs) across four patients' subgroups Results demonstrate that Qoramatic ASM reduces per-patient care costs by 80-94.5% ($242-$1,344 vs. $1,215-$24,615 for pads/IBCs), decreases nursing time 91-96% (6-14 vs. 66-348 min/day), and nearly eliminates leakage and device-related injuries. ASM also reduces HAPI and CDI incidence, shortening hospital stays by up to 30%. Qoramatic's improved clinical outcomes, enhanced patient dignity, and reduced staff burden positioning it is a transformative solution for FI management in ICUs, warranting broader global adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.